Search clinical trials for: CNTO 136

Total 3618 results

Centocor Research & Development, Inc.

Completed

A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous
Centocor, Inc.

Completed

A Study of the Safety and How the Body Effects a Drug CNTO 136 in Healthy Male Japanese and Caucasian Volunteers

Healthy
Janssen Research & Development, LLC

Completed

An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis

Lupus Nephritis

United States, Belgium, Mexico, Poland, Netherlands, Thailand
Janssen Pharmaceutical K.K.

Completed

Safety, Pharmacokinetics, and Pharmacodynamics Study of Single Dose of CNTO 3649 in Healthy Adult Men and Multiple Doses of CNTO 3649 in Participants With Type 2 Diabetes Mellitus

Healthy | Diabetes Mellitus, Type 2

Japan
Centocor, Inc.

Completed

A Study of Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy

Arthritis, Rheumatoid

Poland, United States, Mexico, Korea, Republic of, Japan, Russian Federation, Hungary
Janssen Research & Development, LLC

Completed

A Study of CNTO 3157 in Healthy Normal and Asthmatic Participants Inoculated With Human Rhinovirus Type 16

Healthy Volunteers and Asthma

United Kingdom, Canada, Netherlands, Germany, Denmark, Belgium
Charite University, Berlin, Germany

Unknown

WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

Germany
Charite University, Berlin, Germany

Unknown

WT1 Peptid Vaccination in Carcinomas

WT1 Expressing Carcinoma

Germany
Janssen Research & Development, LLC

Completed

A Safety and Pharmacokinetics Study of CNTO 3157 in Healthy Japanese and Caucasian Participants

Healthy

United States
Capital Medical University

Completed

The Effects of Lowering Dialysate Sodium in Hypertensive Hemodialysis Patients

Arteriosclerosis | Hypertension | Left Ventricular Hypertrophy

China
Centocor, Inc.

Completed

A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CNTO 3649 in Healthy Adults and Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
Janssen Inc.

Completed

A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis (X-PLORE)

Psoriasis

United States, Poland, Canada, Belgium, Germany
Janssen-Cilag International NV

Completed

A Safety, Tolerability, Pharmacokinetics, and Immunogenicity Study of CNTO 6785 in Healthy Volunteers

Healthy

Belgium
National Cancer Institute (NCI)

Completed

SJG-136 in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Terminated

SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | Secondary Acute Myeloid Leukemia and other conditions

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Safety, PK and PD Study in Healthy Male Japanese Subjects

Schizophrenia
Wyeth is now a wholly owned subsidiary of Pfizer

Terminated

Study Evaluating SCA-136 Tolerability With Dose Titration and Food

Healthy

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese and Non-Japanese Female Subjects

Schizophrenia

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese Male Subjects

Schizophrenia

Japan
Janssen Pharmaceutical K.K.

Withdrawn

Efficacy and Safety Study of CNTO 2476 in Participants With Visual Acuity Impairment Associated With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD)

Macular Degeneration | Geographic Atrophy | Visual Acuity

Japan
Janssen Research & Development, LLC

Completed

A Safety and Tolerability Study of 42037788 (Referred to as CNTO 0007) Compared With Placebo in Patients Who Have Experienced Ischemic Cerebral Infarction (Also Known as Stroke)

Infarction | Ischemia | Stroke

United States
Centocor, Inc.

Terminated

A Study to Evaluate the Safety of CNTO 2476 in Patients With Advanced Retinitis Pigmentosa

Retinitis Pigmentosa

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Effectiveness and Safety of CNTO6785 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Poland, Germany, Taiwan, Malaysia, Korea, Republic of, Czech Republic, Russian Federation, Hungary
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study GSI-136 in Healthy Young and Healthy Elderly Subjects

Healthy | Alzheimer Disease

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Safety of GSI 136 in Young and Elderly Japanese Males

Healthy | Alzheimer Disease

Japan
Janssen Research & Development, LLC

Completed

A Single Ascending Dose Study in Healthy Participants and Multiple Ascending Dose Study of CNTO 7160 in Participants With Asthma and Participants With Atopic Dermatitis

Healthy | Asthma | Atopic Dermatitis

Germany, Belgium
Janssen Research & Development, LLC
GlaxoSmithKline

Completed

A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis (SIRROUND-H)

Arthritis, Rheumatoid

United States, Poland, Ukraine, Germany, Spain, Colombia, Mexico, Bulgaria, Romania, Serbia, South Africa, Chile, Russian Federation, Hungary, Lithuania, Moldova, Republic of
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS) | Chronic Myeloid Leukemia (CML)

United States
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety of CNTO 1959 (Guselkumab) in Participants With Moderate to Severe Plaque-type Psoriasis

Psoriasis

Japan
Janssen Research & Development, LLC

Completed

A Study of Subcutaneously-administered Guselkumab Delivered by 3 Different Devices in Healthy Participants

Healthy

United States, Germany
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety Study of CNTO1959 (Guselkumab) in the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Pustular Psoriasis

Japan
Centocor, Inc.

Completed

A Study of the Safety and How the Body Affects a Drug (CNTO 1959) in Healthy Volunteers and in Patients With Psoriasis

Psoriasis

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Dysregulation of Glutamine Activity in the Pathogenesis of Multiple Myeloma

Monoclonal Gammopathy of Undetermined Significance | Plasma Cell Myeloma

United States
NeuShen Therapeutics

Not yet recruiting

First-into-human Study of NS-136 in Healthy Subjects

Healthy Subjects

Australia
Ain Shams University

Completed

Evaluation of Apelin-13 and Apelin-36 in Women With Recurrent Pregnancy Loss

Recurrent Pregnancy Loss

Egypt
Robert Bok, MD, PhD
National Cancer Institute (NCI); National Institute for Biomedical Imaging... and other collaborators

Recruiting

Hyperpolarized 13C Pyruvate as a Biomarker in Advanced Solid Tumors

Advanced Solid Tumor

United States
Centocor, Inc.

Completed

A Phase 1 Study of CNTO 3157 in Healthy Volunteers and Patients With Asthma

Asthma

Germany, United Kingdom, Belgium
Janssen Research & Development, LLC

Active, not recruiting

A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis (THEIA)

Giant Cell Arteritis

United States, Canada, Belgium, Israel, Italy, Germany, France, Spain, Poland
Chang Gung Memorial Hospital
Ministry of Science and Technology, Taiwan

Recruiting

Hyperpolarized 13C Pyruvate MRI for Early Immune Evaluation in Cervical Cancer Patients at Baseline and CCRT Therapy

Cervical Cancer

Taiwan
Centre Hospitalier Universitaire Dijon

Completed

Study of the T CD8 Immune Response in Horton's Disease (Horton CD8)

Horton's Disease

France
Centocor Research & Development, Inc.

Completed

A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis

Psoriasis

United States, United Kingdom, Germany, Canada, Austria, France, Switzerland
Robert Flavell, MD, PhD
U.S. Army Medical Research Acquisition Activity

Recruiting

Magnetic Resonance (MR) Imaging With Hyperpolarized Bicarbonate (13C) to Measure Tissue pH in Prostate Cancer

Prostate Cancer | Localized Prostate Carcinoma

United States
Janssen Research & Development, LLC

Completed

A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus

Healthy | Systemic Lupus Erythematosus

United States, Spain, Romania, Taiwan, Belgium, Poland, Moldova, Republic of
Centocor, Inc.

Completed

A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Pulmonary Fibrosis

United States, Canada, Netherlands, Belgium, Germany
Centocor, Inc.

Completed

First Study of the Safety of CNTO 888 in Patients With Solid Tumors

Cancer
Janssen Pharmaceutical K.K.

Completed

A Study of the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody in Participants With Palmoplantar Pustulosis

Palmoplantaris Pustulosis

Japan
Janssen Research & Development, LLC

Completed

A Safety Study of CNTO 2476 in Patients With Age-Related Macular Degeneration

Age-related Macular Degeneration

United States
National Cancer Institute (NCI)

Completed

SJG-136 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery

Unspecified Adult Solid Tumor, Protocol Specific

United States
Sir Run Run Shaw Hospital

Recruiting

The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma

Rectal Adenocarcinoma

China
Janssen Pharmaceutical K.K.

Completed

A Study of the Safety, Tolerability, Pharmacokinetics (What the Body Does to the Drug), and Pharmacodynamics (What the Drug Does to the Body) of CNTO 1959 Following a Single Subcutaneous (Under the Skin) Administration in Japanese Participants With Moderate to Severe Plaque Psoriasis

Psoriasis

Japan

3

Subscribe